×
About 144,270 results

ALLMedicine™ Schizophrenia Center

Research & Reviews  68,223 results

Prevalence and Outcomes of Major Psychiatric Disorders Preceding Index Surgery for Dege...
https://doi.org/10.3390/ijerph18105391
International Journal of Environmental Research and Publi... Huang YC, Chang CH et. al.

Jun 2nd, 2021 - The relationship between preexisting major psychiatric disorders and outcomes of spine surgery for degenerative thoracic/lumbar disease remains unclear. A 5% subset of inpatients was randomly selected from the Taiwan National Health Insurance Rese...

Effects of a Short Emotional Management Program on Inpatients with Schizophrenia: A Pil...
https://doi.org/10.3390/ijerph18105497
International Journal of Environmental Research and Publi... Park KH, Park ES et. al.

Jun 2nd, 2021 - The prevalence of schizophrenia is gradually increasing worldwide. Many patients with schizophrenia have a diminished ability to empathize and to detect their own emotions or those of others, deteriorating their social functioning and their qualit...

The Role of Social Stress in the Development of Inhibitory Control Deficit: A Systemati...
https://doi.org/10.3390/ijerph18094953
International Journal of Environmental Research and Publi... Sánchez-Salvador L, Prados-Pardo Á et. al.

Jun 2nd, 2021 - Inhibitory control deficit and impulsivity and compulsivity behaviours are present in different psychopathological disorders such as addiction, obsessive-compulsive disorders and schizophrenia, among others. Social relationships in humans and anim...

Anomalous self-experiences in cognition are negatively associated with neurocognitive f...
https://doi.org/10.1080/13546805.2021.1935225
Cognitive Neuropsychiatry; Trask CL, Matsui MM et. al.

Jun 1st, 2021 - Anomalous self-experiences (ASEs) are disturbances in the subjective experience of the self and are common in people with schizophrenia. Theorists have suggested that ASEs may underlie the neurocognitive deficits that are also common in people wit...

Reduced adult neurogenesis is associated with increased macrophages in the subependymal...
https://doi.org/10.1038/s41380-021-01149-3 10.1016/S0140-6736(13)61611-6 10.1038/s41588-019-0397-8 10.1038/nature13595 10.1038/nrdp.2018.8 10.1016/j.schres.2014.02.021 10.1503/jpn.100048 10.1038/tp.2014.8 10.1016/S0920-9964(01)00188-8 10.1016/j.nbd.2018.06.020 10.3389/fnana.2020.581685 10.1523/JNEUROSCI.23-15-06315.2003 10.1176/appi.ajp.2010.09060784 10.1111/ejn.13623 10.3389/fnagi.2016.00274 10.1016/j.cell.2014.01.044 10.1038/s41591-019-0375-9 10.1016/j.stem.2018.03.015 10.1007/s00406-019-01066-1 10.1016/j.cell.2013.05.002 10.1111/nan.12337 10.1038/nature25975 10.1177/0004867415589793 10.1038/sj.mp.4001791 10.1073/pnas.92.7.2785 10.1038/tp.2012.56 10.1093/schbul/sbv157 10.2174/157488912803251998 10.1038/mp.2016.8 10.1016/j.biopsych.2013.05.031 10.1038/nature02301 10.1016/j.celrep.2016.12.060 10.1126/science.aaf7073 10.1002/1096-9861(20000731)423:3<359::AID-CNE1>3.0.CO;2-0 10.1093/schbul/sby016.472 10.1038/npp.2014.230 10.1016/j.schres.2013.09.007 10.1073/pnas.97.20.11032 10.1002/jnr.10281 10.1038/sj.npp.1300422 10.1016/j.euroneuro.2015.08.004 10.1007/s00213-015-4044-5 10.1046/j.1460-9568.2001.01633.x 10.1523/JNEUROSCI.20-24-09104.2000 10.1016/j.imbio.2016.07.001 10.1016/j.neuropharm.2008.07.014 10.1111/j.1601-183X.2006.00298.x 10.1038/nn1345 10.1016/j.devcel.2015.01.010 10.1038/ncb2001 10.1523/JNEUROSCI.4987-09.2010 10.1523/JNEUROSCI.0001-17.2017 10.1016/j.tins.2014.12.006 10.1038/npp.2011.277 10.1523/JNEUROSCI.1217-15.2015 10.1016/j.neuroscience.2008.06.052 10.1016/j.mcn.2005.10.006 10.1038/nrneurol.2014.207 10.1038/mp.2012.110 10.1016/j.jpsychires.2014.02.014 10.1038/sj.mp.4001308 10.1038/s41380-018-0235-x 10.1038/mp.2009.128 10.1111/j.1474-9726.2010.00556.x 10.1172/JCI59145 10.1038/nature10487 10.1016/j.neuron.2019.09.026 10.1016/j.molmed.2018.04.002 10.3389/fnana.2015.00074 10.1038/cr.2011.83 10.1097/YCO.0000000000000501 10.1038/tp.2013.94 10.1016/j.bbi.2012.08.005 10.1038/tp.2016.229 10.1016/j.stem.2008.07.025 10.4049/jimmunol.0801218 10.1073/pnas.2234031100 10.1038/nature16549 10.1523/JNEUROSCI.3617-10.2011 10.1371/journal.pone.0038664 10.1016/j.bbi.2019.08.004 10.1007/s13238-016-0250-0 10.1038/nrn3024 10.1038/ncomms2895 10.1038/s41598-018-23703-w 10.1038/s41398-017-0052-z 10.1371/journal.pone.0038172 10.1016/j.neuroscience.2007.03.051 10.1073/pnas.0506713102 10.1038/s41588-018-0129-5 10.1038/s41467-018-08023-x 10.1186/s13073-017-0458-5 10.1016/j.biopsych.2004.07.008 10.1016/j.brainres.2005.11.047 10.1038/mp.2013.8
Molecular Psychiatry; Weissleder C, North HF et. al.

Jun 1st, 2021 - Neural stem cells in the human subependymal zone (SEZ) generate neuronal progenitor cells that can differentiate and integrate as inhibitory interneurons into cortical and subcortical brain regions; yet the extent of adult neurogenesis remains une...

see more →

Guidelines  47 results

The American Psychiatric Association Practice Guideline for the Treatment of Patients W...
https://doi.org/10.1176/appi.ajp.2020.177901
The American Journal of Psychiatry; Keepers GA, Fochtmann LJ et. al.

Sep 1st, 2020 - The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.|2020|Keepers GA,Fochtmann LJ,Anzia JM,Benjamin S,Lyness JM,|methods,methods,methods,classification,therapeutic use,diagnosis,therapy,

CAPLYTA® (lumateperone) | Now Approved | caplyta.com‎
https://www.caplyta.com/‎

Jan 13th, 2020 - Learn about a new treatment. See full safety information, PI, and boxed warning. Get information about this orally administered capsule. Press Release. Prescribing Information. MOA. Important Safety Info. Dosing & Administration.

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated r...
https://doi.org/10.1177/0269881119889296
Journal of Psychopharmacology (Oxford, England); Barnes TR, Drake R et. al.

Dec 12th, 2019 - These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, i...

Cannabidiol as a potential treatment for psychosis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843725/
Therapeutic Advances in Psychopharmacology; Davies C,et al

Nov 7th, 2019 - Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treat...

U.S. FDA Approves SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia
http://www.noven.com/PR101519.php

Oct 14th, 2019 - Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Administration (FDA) has approved SECUADO® (asenapine) transdermal system, the first-and-only transdermal patch fo...

see more →

Drugs  1,713 results see all →

Clinicaltrials.gov  71,553 results

Prevalence and Outcomes of Major Psychiatric Disorders Preceding Index Surgery for Dege...
https://doi.org/10.3390/ijerph18105391
International Journal of Environmental Research and Publi... Huang YC, Chang CH et. al.

Jun 2nd, 2021 - The relationship between preexisting major psychiatric disorders and outcomes of spine surgery for degenerative thoracic/lumbar disease remains unclear. A 5% subset of inpatients was randomly selected from the Taiwan National Health Insurance Rese...

Once-Weekly Oral Antipsychotic for Schizophrenia on the Horizon 
https://www.medscape.com/viewarticle/952426

Jun 2nd, 2021 - A novel, ultra-long-acting oral formulation of the antipsychotic risperidone (Risperdal) only needs to be taken once weekly and appears to be safe and effective, results of a new phase 2 study suggest. The new formulation, LYN-005 (Lyndra Therapeu...

Effects of a Short Emotional Management Program on Inpatients with Schizophrenia: A Pil...
https://doi.org/10.3390/ijerph18105497
International Journal of Environmental Research and Publi... Park KH, Park ES et. al.

Jun 2nd, 2021 - The prevalence of schizophrenia is gradually increasing worldwide. Many patients with schizophrenia have a diminished ability to empathize and to detect their own emotions or those of others, deteriorating their social functioning and their qualit...

The Role of Social Stress in the Development of Inhibitory Control Deficit: A Systemati...
https://doi.org/10.3390/ijerph18094953
International Journal of Environmental Research and Publi... Sánchez-Salvador L, Prados-Pardo Á et. al.

Jun 2nd, 2021 - Inhibitory control deficit and impulsivity and compulsivity behaviours are present in different psychopathological disorders such as addiction, obsessive-compulsive disorders and schizophrenia, among others. Social relationships in humans and anim...

Schizophrenia Meds a Key Contributor to Cognitive Impairment
https://www.medscape.com/viewarticle/952412

Jun 2nd, 2021 - Anticholinergic medication burden from antipsychotics, antidepressants, and other psychotropics has a cumulative effect of worsening cognitive function in patients with schizophrenia, new research indicates. "The link between long-term use of anti...

see more →

News  2,701 results

Once-Weekly Oral Antipsychotic for Schizophrenia on the Horizon 
https://www.medscape.com/viewarticle/952426

Jun 2nd, 2021 - A novel, ultra-long-acting oral formulation of the antipsychotic risperidone (Risperdal) only needs to be taken once weekly and appears to be safe and effective, results of a new phase 2 study suggest. The new formulation, LYN-005 (Lyndra Therapeu...

Schizophrenia Meds a Key Contributor to Cognitive Impairment
https://www.medscape.com/viewarticle/952412

Jun 2nd, 2021 - Anticholinergic medication burden from antipsychotics, antidepressants, and other psychotropics has a cumulative effect of worsening cognitive function in patients with schizophrenia, new research indicates. "The link between long-term use of anti...

FDA Okays New Drug Option for Schizophrenia, Bipolar I Disorder
https://www.medscape.com/viewarticle/952177

May 31st, 2021 - The US Food and Drug Administration (FDA) has approved a once-daily oral medication, which is a combination of olanzapine and samidorphan (Lybalvi, Alkermes), for the treatment of schizophrenia and bipolar I disorder. The drug is approved for the ...

FDA Fast Tracks Testing of Schizophrenia Drug for Impaired Cognition
https://www.medscape.com/viewarticle/951880

May 25th, 2021 - The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Boehringer Ingelheim's experimental agent for the treatment of cognitive impairment associated with schizophrenia (CIAS). The drug, known as BI 425809, is a...

Psychiatric Disorder Prevalence Higher in Adult Cerebral Palsy
https://www.medscape.com/viewarticle/951707

May 23rd, 2021 - Adults with cerebral palsy, especially those with intellectual disabilities, are significantly more likely to be diagnosed with a psychiatric disorder, compared with the general population, a review of seven datasets shows. The body of literature ...

see more →

Patient Education  33 results see all →